TF Capital

TF Capital is a Shanghai-based life sciences specialist known for identifying and scaling novel therapeutic modalities and regenerative medicine companies, with broader biotech and life sciences tools exposure across seed through Series B. The thesis suggests interest in cutting-edge platform science such as cell and gene therapies, regenerative biology, and the tooling layer that supports their commercialization. The Shanghai base positions the firm at the center of China’s biotech ecosystem, with proximity to relevant research institutions, hospitals, and regulatory bodies. Limited public information about named partners, specific portfolio companies, and detailed fund vintages is available in English-language sources.

Check sizes range from 1 million to 5 million dollars across seed, Series A, and Series B, suited for IND-enabling work, early clinical advancement, manufacturing build-out, and platform expansion in capital-intensive life sciences companies. Geography centers on China with Shanghai as the base, and the firm is well-suited to founders pursuing development within Chinese clinical and regulatory frameworks. Companies operating purely outside the Chinese life sciences ecosystem will not match the thesis.

The approach suits scientist-founders building therapeutic platforms or supporting life sciences tools in advanced modalities, who want investors fluent in cell and gene therapy regulatory pathways, manufacturing requirements, and the realism of long development timelines. Founders expecting fast commercial traction or quick markups should calibrate accordingly. Initial conversations should focus on the company’s platform science, IND or clinical trial timeline, and the specific operational support TF Capital offers beyond capital, particularly around CDMO relationships, hospital partnerships for trials, and downstream syndicate construction for later rounds.